The FDA has announced the approval of Combivent Respimat (ipratropium bromide and albuterol sulfate) Inhalation Spray for patients with Chronic...
Boehringer Ingelheim announced that the FDA approved once-daily Stiolto Respimat (tiotropium bromide and olodaterol) Inhalation Spray as a long-term, once-daily...
Boehringer Ingelheim has announced new data that show increase in FEV1 AUC0–12, a measure of lung function, with Stiolto Respimat...
The German Institute for Quality and Efficiency in Health Care (IQWiG) has examined in a dossier assessment whether the fixed-dose...
Boehringer announced that the FDA approved new labeling for Stiolto Respimat (tiotropium bromide & olodaterol) Inhalation Spray that includes data...
Boehringer Ingelheim announced regulatory authority approvals for Spiolto Respimat (tiotropium/olodaterol) in first European countries. Spiolto Respimat is a once-daily maintenance...
Data from the Phase III clinical program show the use of Striverdi Respimat (olodaterol), from Boehringer, provided improvements in lung...
Boehringer Ingelheim announced that the indication for Spiriva (tiotropium) Respimat in Asthma has been accepted by the regulatory authorities in...
The FDA approved a sNDA for Stiolto Respimat (olodaterol + tiotropium), from Boehringer, that adds data showing improvement in health-related...